Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1988 Oct;26(4):481–485. doi: 10.1111/j.1365-2125.1988.tb03410.x

Topical minoxidil: cardiac effects in bald man.

F H Leenen 1, D L Smith 1, W P Unger 1
PMCID: PMC1386573  PMID: 3191000

Abstract

Systemic cardiovascular effects during chronic treatment with topical minoxidil vs placebo were evaluated using a double-blind, randomized design for two parallel groups (n = 20 for minoxidil, n = 15 for placebo). During 6 months of follow-up, blood pressure did not change, whereas minoxidil increased heart rate by 3-5 beats min-1. Compared with placebo, topical minoxidil caused significant increases in LV end-diastolic volume, in cardiac output (by 0.751 min-1) and in LV mass (by 5 g m-2). We conclude that in healthy subjects short-term use of topical minoxidil is likely not to be detrimental. However, safety needs to be established regarding ischaemic symptoms in patients with coronary artery disease as well as for the possible development of LV hypertrophy in healthy subjects during years of therapy.

Full text

PDF
481

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson K. P. Sudden death, hypertension, and hypertrophy. J Cardiovasc Pharmacol. 1984;6 (Suppl 3):S498–S503. [PubMed] [Google Scholar]
  2. De Villez R. L. Topical minoxidil therapy in hereditary androgenetic alopecia. Arch Dermatol. 1985 Feb;121(2):197–202. doi: 10.1001/archderm.121.2.197. [DOI] [PubMed] [Google Scholar]
  3. Feinstein R. P. The effect of topical minoxidil on blood pressure. J Am Acad Dermatol. 1985 Oct;13(4):673–674. doi: 10.1016/s0190-9622(85)80455-2. [DOI] [PubMed] [Google Scholar]
  4. Franz T. J. Percutaneous absorption of minoxidil in man. Arch Dermatol. 1985 Feb;121(2):203–206. [PubMed] [Google Scholar]
  5. Gottlieb T. B., Katz F. H., Chidsey C. A., 3rd Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972 Mar;45(3):571–582. doi: 10.1161/01.cir.45.3.571. [DOI] [PubMed] [Google Scholar]
  6. Leenen F. H., Smith D. L., Farkas R. M., Reeves R. A., Marquez-Julio A. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans. Am J Med. 1987 May;82(5):969–978. doi: 10.1016/0002-9343(87)90160-4. [DOI] [PubMed] [Google Scholar]
  7. Levy D., Anderson K. M., Savage D. D., Balkus S. A., Kannel W. B., Castelli W. P. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol. 1987 Sep 1;60(7):560–565. doi: 10.1016/0002-9149(87)90305-5. [DOI] [PubMed] [Google Scholar]
  8. Man in 't Veld A. J., Wenting G. J., Boomsma F., Verhoeven R. P., Schalekamp M. A. Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. Br J Clin Pharmacol. 1980 Jun;9(6):547–551. doi: 10.1111/j.1365-2125.1980.tb01079.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Murphy M. B., Scriven A. J., Brown M. J., Causon R., Dollery C. T. The effects of nifedipine and hydralazine induced hypotension on sympathetic activity. Eur J Clin Pharmacol. 1982;23(6):479–482. doi: 10.1007/BF00637492. [DOI] [PubMed] [Google Scholar]
  10. Olsen E. A., DeLong E. R., Weiner M. S. Dose-response study of topical minoxidil in male pattern baldness. J Am Acad Dermatol. 1986 Jul;15(1):30–37. doi: 10.1016/s0190-9622(86)70138-2. [DOI] [PubMed] [Google Scholar]
  11. Olsen E. A., Weiner M. S., Delong E. R., Pinnell S. R. Topical minoxidil in early male pattern baldness. J Am Acad Dermatol. 1985 Aug;13(2 Pt 1):185–192. doi: 10.1016/s0190-9622(85)70157-0. [DOI] [PubMed] [Google Scholar]
  12. Ranchoff R. E., Bergfeld W. F. Topical minoxidil reduces blood pressure. J Am Acad Dermatol. 1985 Mar;12(3):586–587. doi: 10.1016/s0190-9622(85)80102-x. [DOI] [PubMed] [Google Scholar]
  13. Reeves R. A., Smith D. L., Leenen F. H. Hemodynamic interaction of nonselective vs. beta-1-selective beta-blockade with hydralazine in normal humans. Clin Pharmacol Ther. 1987 Mar;41(3):326–335. doi: 10.1038/clpt.1987.35. [DOI] [PubMed] [Google Scholar]
  14. Tarazi R. C., Dustan H. P., Bravo E. L., Niarchos A. P. Vasodilating drugs: contrasting haemodynamic effects. Clin Sci Mol Med Suppl. 1976 Dec;3:575s–578s. doi: 10.1042/cs051575s. [DOI] [PubMed] [Google Scholar]
  15. Tsoporis J., Leenen F. H. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats. Hypertension. 1988 Apr;11(4):376–386. doi: 10.1161/01.hyp.11.4.376. [DOI] [PubMed] [Google Scholar]
  16. Vanderveen E. E., Ellis C. N., Kang S., Case P., Headington J. T., Voorhees J. J., Swanson N. A. Topical minoxidil for hair regrowth. J Am Acad Dermatol. 1984 Sep;11(3):416–421. doi: 10.1016/s0190-9622(84)70183-6. [DOI] [PubMed] [Google Scholar]
  17. Zacest R., Gilmore E., Koch-Weser J. Treatment of essential hypertension with combined vasodilation and beta-adrenergic blockade. N Engl J Med. 1972 Mar 23;286(12):617–622. doi: 10.1056/NEJM197203232861201. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES